Navigation Links
iZumi Bio, Inc., Appoints John Walker as Chief Executive Officer
Date:2/12/2009

MOUNTAIN VIEW, Calif., Feb. 12 /PRNewswire/ -- iZumi Bio, Inc., announced today the appointment of John P. Walker as Chief Executive Officer and a member of the company's Board of Directors. Walker was most recently the Chairman and CEO of Novacea, Inc. which merged with Transcept Pharmaceuticals Inc. in January 2009.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080806/AQW065LOGO)

iZumi Bio is focused on the development of induced pluripotent stem (iPS) cell technology to transform drug discovery and enable the promise of regenerative medicine.

"This is an exceptionally exciting time to be joining iZumi Bio, as we are seeing an increasing interest in the promise of stem cells to transform many aspects of the pharmaceutical industry," said Walker. "iZumi Bio has a leading position in industrializing the potential of iPS cells. Our goal is to create fully annotated, disease specific human cell lines that will fundamentally change the way in which small molecule drug discovery and development will be conducted in the future."

He continued, "Additionally, the development of these differentiated cell lines will enable the development of patient specific and cell replacement therapies."

Prior to joining Novacea, Walker, serving as a consultant and investor, was Executive Chairman and Principal Executive Officer of Renovis Inc.; Chairman and Interim CEO of Guava Technologies; KAI Pharmaceuticals and Centaur Pharmaceuticals; and Chairman and CEO of Bayhill Therapeutics. From 1993 to 2001, he was Chairman and CEO of Arris Pharmaceuticals and its successor corporation AXYS Pharmaceuticals Inc., and previously was Chairman and CEO of Vitaphore Corporation.

Walker began his career with American Hospital Supply Corporation, where he last served as President of the American Hospital Company. His many board experiences have included serving as Chairman of Signal Pharmaceuticals and Microcide Pharmaceuticals Inc., and a director of Geron Corporation, Discovery Partners Inc., and several other private companies.

"We are very pleased to have John joining iZumi Bio as CEO," explained Beth Seidenberg M.D., a partner at Kleiner Perkins Caufield & Byers and Chairperson of iZumi Bio. "His considerable experience across a wide range of companies, therapeutic areas and technologies, including human embryonic stem cells, will help accelerate the full realization of iZumi Bio's iPS technology."

Walker received a B.A. from the State University of New York at Buffalo and is a graduate of the Advanced Executive Program, J. L. Kellogg Graduate School of Management at Northwestern University. He currently serves on the Board of Directors of Affymax, Inc., Transcept Pharmaceuticals, Inc., and Evotec AG.

About iZumi Bio, Inc.

iZumi Bio, Inc. was founded in 2007 and is funded by Kleiner Perkins Caufield and Byers and Highland Capital Partners. iZumi Bio is using the power of induced pluripotent stem cells (iPS) to transform drug discovery and enable the promise of regenerative medicine. In June 2008, iZumi Bio announced a broad regenerative medicine and cardiovascular disease partnership with The Gladstone Institutes. The name iZumi, which in Japanese means "fountain of youth," was chosen to honor the Japanese origins of iPS technology. iZumi Bio is located in the San Francisco Bay Area.


'/>"/>
SOURCE iZumi Bio, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. The Gladstone Institutes and iZumi Bio Announce Broad Partnership in Regenerative Medicine and Cardiovascular Disease
2. iZumi Bio, Inc. Recruits Leading iPS Scientist, John Dimos, to Translate Stem Cell Breakthrough Into Patient Benefits
3. BSP Pharma Inc., Makers of FlexNow(TM) Joint Formula Sign Distribution Deal with Vitamin Shoppe and GNC
4. The PLSG Invests $150,000 in Coventina Healthcare Enterprises, Inc., Its Eighth Company Relocation to Pittsburgh
5. Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures
6. Respironics Acquires Apollo Light Systems, Inc., Expands into Circadian Rhythm Device-Based Therapy Market
7. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
8. LS9, Inc., the Renewable Petroleum Company(TM), Adds Key Positions to Executive Team and Scientific Advisory Board
9. IBF Conferences Inc., (International Business Forum) and BioEnterprise Present the 2nd Annual Global Healthcare Investing Conference
10. M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer
11. Elsevier Acquires Windhover Information Inc., a Healthcare Business Intelligence Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... Cancer experts from Austria, Hungary, Switzerland, and ... new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma has just published ... , Biomarkers are components in the blood, tissue or body fluids that ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... ... 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers use ... 6000i models are higher end machines that use the more unconventional z-dimension of 20mm. ... from the bottom of the cuvette holder. , FireflySci has developed several Agilent ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
Breaking Biology Technology:
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
Breaking Biology News(10 mins):